Ben Morris
Papers
1
Total Citations
32
H-Index
1
About
Ben Morris is a researcher whose work lies at the intersection of cancer biology and drug discovery, with a particular focus on DNA damage response pathways and radiosensitization. His most cited contribution, a 2017 study identifying a novel ATM inhibitor with cancer cell-specific radiosensitization activity, has garnered 32 citations and represents a significant advance in targeted cancer therapy. This work demonstrates how selective inhibition of ATM—a key kinase in the DNA damage response—can enhance the effectiveness of radiation therapy specifically in cancer cells while potentially sparing normal tissues, addressing a critical challenge in oncology. Morris's research combines mechanistic understanding of cellular signaling with translational applications, contributing to the development of more precise cancer treatments. His collaborative approach, working alongside experts in head and neck oncology, chemical biology, and immunology, underscores the interdisciplinary nature of his investigations. For students and researchers interested in the frontier of radiosensitizers and targeted cancer therapies, Morris's work offers a compelling example of how fundamental insights into cellular stress responses can be translated into potential clinical strategies that may improve outcomes for patients undergoing radiation treatment.
Research Focus
Key Achievements
Top Papers
- 1